newsfilter
← Latest News
GlobeNewswire·

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential